Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

May 2, 2024

https://www.globenewswire.com/news-release/2024/05/02/2874639/0/en/Vor-Bio-Appoints-Accomplished-Oncology-and-Cancer-Immunotherapy-R-D-Executive-Fouad-Namouni-M-D-to-its-Board-of-Directors.html

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq:VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint Medicines, bringing a wealth of industry experience and expertise to Vor Bio’s Board.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.